This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo
by Zacks Equity Research
CYTK secures EU approval for Myqorzo in symptomatic obstructive HCM, expanding its first commercial drug across major global markets.
BMYPositive Net Change ALKSNegative Net Change CYTKNegative Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?
by Ekta Bagri
BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.
BMYPositive Net Change MRKPositive Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA talks.
AXSMPositive Net Change CSTLNegative Net Change IMVTPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
What to Expect From These Drug/Biotech Players This Earnings Season?
by Ekta Bagri
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
BMRNPositive Net Change FOLDPositive Net Change INSMNegative Net Change MDGLNegative Net Change BHCNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock sinks 21% in a month as weak 2026 guidance, slowing semaglutide sales, and rising competition overshadow relatively strong Q4 results.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
ServisFirst Bancshares (SFBS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SFBSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Near-Perfect CPI Report Brings Pre-Markets Near Breakeven
by Mark Vickery
Pre-market futures had been wallowing in negative territory ahead of this print, but are now pushing toward breakeven at this hour.
NVDANegative Net Change WENNegative Net Change AAPPositive Net Change MRNAPositive Net Change
biotechnology consumer-discretionary earnings inflation
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia
by Zacks Equity Research
Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.
NVSPositive Net Change ALKSNegative Net Change BAYRYNegative Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
RARE posts a wider-than-expected Q4 loss even as revenues jump 25% to $207 million, beating estimates. It also announces a strategic restructuring plan targeting profitability in 2027.
REGNPositive Net Change ALKSNegative Net Change RAREPositive Net Change CSTLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down
by Zacks Equity Research
Alnylam tops Q4 earnings estimates but misses on sales despite 85% revenue growth, as booming Amvuttra demand fails to lift shares.
ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change ALKSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals